Novo Nordisk CEO tells investors to expect weight-loss drug pricing to go down before it comes back up
Recently-appointed CEO Mike Doustdar has repeatedly reset expectations since his arrival. Pricing and regulatory pressure is fierce an...
BMO Raises Novo Nordisk A/S (NVO) Price Target but Flags Prescription Pressures
Novo Nordisk A/S (NYSE:NVO) is among the